Central Asian Journal of Medicine


Chronic viral hepatitis (CVH) is the focus of medical science and practical health care. In about 80% of patients, the disease becomes chronic. Timely diagnosis of these conditions is the key to developing optimal patient management tactics and preventing complications. Liver fibrosis is reversible; it is a key pathological process in the development of all chronic liver diseases The last decade has been accompanied by the emergence of a large number of studies on the role of small, non-coding RNA molecules (micro-RNAs). The key role of micro-RNA in the disturbance of the balance of proliferation, differentiation and programmed cell death in the development of various diseases, including liver pathology, was revealed. The micro-RNA profile often differs between cells of different tissues, which in turn can help determine, predict the response to therapy and determine the prognosis of the course of the disease. In view of the fact that the stage of liver fibrosis is a priority in the choice of treatment tactics, it remains relevant to search for predictors of an unfavorable outcome. Molecular genetic mechanisms of the development of fibrosis regulate the synthesis and breakdown of collagen. The prevalence of one or another nomenclature of miRNAs can provide information about active fibrogenesis, therefore, can develop a rapid replacement of the hepatic tissue with fibrous tissue. Research in this area will make it possible to get closer to understanding the mechanisms of the formation of such complications of chronic viral hepatitis as cirrhosis of the liver and hepatocellular carcinoma. Object: to study the expression level of miRNA-122 as a predictor of the risk of complications in patients with chronic viral hepatitis. Material and methods: to study the role of microRNA-122 in the study, 32 patients were isolated from the total number of examined patients: of them 17 (53.1%) with a diagnosis of chronic viral hepatitis made up 1 subgroup and 15 (46.9%) with a diagnosis of compensated liver cirrhosis 2 subgroup. The expression level of miRNA-122 in blood plasma was measured by reverse transcription PCR in accordance with the TaqMan miRNA analysis protocol. Results: the intervals of the range of the expression level of miR-122 looked as follows, the division was four-level from the minimum values of 0.001 - 0.14; 0.15 -1.05; 1.05 - 12.88 and> 12.89. The lowest levels of miRNA-122 were found in patients with severe hepatic fibrosis as indicators of the functional capacity of the liver.

First Page


Last Page



1. Bala S., Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drugeases / Bala S., Petrasek J., Mundkur S. [et al.] // Hepatology. - 2012. - Vol. 56. - P. 1946-1957. 2. Blancooa A Circulating microRNAs: molecular microsensors in gastrointestinal can cer / Blancooa A. [et al.] // Sensors (Basel). - 2012. - Vol. 12. - P. 9349-9362 3. Cermelli S. Circulating microRNAs in patients with chronic hepatitis C and non J. A. Marrero // PLoS One 6. - 2011. - e23937. 4. Elfimova N. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA / Elfimova N. et al. // PLoS One. - 2011. - Vol. 6. - e 24568. 5. Gao B .. Alcoholic liver disease: pathogenesis and new the rapeutic targets / B. Gao and Bataller R // Gastroenterology. - 2011. - Vol. 141.- a. 1572-1585. 6. Gui J. Serum microRNA characterization identifies miR al marker for detecting liver pathologies / Gui J., Tian Y., Wen X. [et al.] // Clin. Sci (Lond). - 2011. - Vol. 120. - P. 183-193. 7. Ji J. MicroRNA expression, survival, and response to interferon in liver can cer / Ji J., Shi J., Budhu A. [et al.] // N. Engl. J. Med. - 2009. - Vol. 361. - P. 1437-1447. 8. Marquez R. T., Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans / Marquez R. T., Bandyopadhyay S., Wendlandt E. B. [et al.] // Lab Invest. - 2010. - Vol. 90. - P. 1727-1736. 9. Roderburg C. Microofiling reveals a role for miRfibrosis / Roderburg C., Urban G. W., Bettermann K. [et al.] // Hepatolo gy. - 2011. - Vol. 53. - P. 209-218. 10. S. Ryder. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study / S. Ryder et al. // Gut. - 2004. - V. 53. - P. 451 - 455. 11. Shu J. Genomewide microRNA downegulation as a negative feedback mechanism in the early phases of liver regeneration / Shu J., Kren B. T., Xia Z. [et al.] // Hepatology. - 2011. - Vol. 54. - P. 609-619. 12. Winter T. N Differential plasma MicroRNK Profiles in HBeAg Positive and HBeAg Nega tive Children with Cronic Hepatitis B / Winter T. N., Bang Heiberg I. L., [et al.] // PLOS ONE. - 2013. - Vol. 8, Issue 3. - P. 58236. 13. Zaret K. S. Regulatory phases of early liver development: paradigms of organogenesis / K. S. Zaret // Nat Rev Genet. - 2002. - Vol. 3.- 499-512.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.